NO20022221L - En fremgangsmåte til en kjemisk forhindring av prostatakreft - Google Patents
En fremgangsmåte til en kjemisk forhindring av prostatakreftInfo
- Publication number
- NO20022221L NO20022221L NO20022221A NO20022221A NO20022221L NO 20022221 L NO20022221 L NO 20022221L NO 20022221 A NO20022221 A NO 20022221A NO 20022221 A NO20022221 A NO 20022221A NO 20022221 L NO20022221 L NO 20022221L
- Authority
- NO
- Norway
- Prior art keywords
- prostate cancer
- procedure
- chemical prevention
- prevents
- chemopreventive agent
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/05—Phenols
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/01—Hydrocarbons
- A61K31/015—Hydrocarbons carbocyclic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4535—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/32—Antioestrogens
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Urology & Nephrology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Foreliggende oppfinnelse angår kjemoprevensjon av prostatakreft og mer spesielt til en metode til å undertrykke eller inhibere latent prostatakreft som omfatter å administrere til et pattedyrindivid et kjemopreventivt middel og analoger og metabolitter derav. Det kjemopreventive middelet forhindrer, forhindrer gjentakelse av, undertrykker eller inhiberer prostatacarcinogenese og behandler prostatakreft.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US43620899A | 1999-11-08 | 1999-11-08 | |
US09/531,472 US6413533B1 (en) | 1998-05-07 | 2000-03-20 | Method for chemoprevention of prostate cancer |
PCT/US2000/030658 WO2001034117A1 (en) | 1999-11-08 | 2000-11-08 | A method for chemoprevention of prostate cancer |
Publications (2)
Publication Number | Publication Date |
---|---|
NO20022221D0 NO20022221D0 (no) | 2002-05-08 |
NO20022221L true NO20022221L (no) | 2002-06-28 |
Family
ID=27030854
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO20022221A NO20022221L (no) | 1999-11-08 | 2002-05-08 | En fremgangsmåte til en kjemisk forhindring av prostatakreft |
Country Status (20)
Country | Link |
---|---|
US (1) | US6413533B1 (no) |
EP (1) | EP1229903A4 (no) |
JP (1) | JP2003513903A (no) |
KR (2) | KR100793721B1 (no) |
CN (1) | CN1331463C (no) |
AU (1) | AU782444B2 (no) |
BG (1) | BG65794B1 (no) |
CA (1) | CA2390295C (no) |
CZ (1) | CZ20021763A3 (no) |
HK (1) | HK1057000A1 (no) |
HR (1) | HRP20020422A2 (no) |
HU (1) | HUP0203304A3 (no) |
IL (1) | IL149545A0 (no) |
IS (1) | IS6375A (no) |
MX (1) | MXPA02004676A (no) |
NO (1) | NO20022221L (no) |
PL (1) | PL354726A1 (no) |
SK (1) | SK8162002A3 (no) |
WO (1) | WO2001034117A1 (no) |
YU (1) | YU43002A (no) |
Families Citing this family (31)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20030130316A1 (en) * | 2000-03-20 | 2003-07-10 | Steiner Mitchell S. | Method for chemoprevention of prostate cancer |
US20040186185A1 (en) * | 1998-05-07 | 2004-09-23 | Steiner Mitchell S. | Method for treatment and chemoprevention of prostate cancer |
US20040092602A1 (en) * | 1998-05-07 | 2004-05-13 | Steiner Mitchell S. | Method for treatment and chemoprevention of prostate cancer |
CA2777199A1 (en) | 2001-07-09 | 2003-01-23 | Repros Therapeutics Inc. | Methods and materials for the treatment of testosterone deficiency in men |
US7737185B2 (en) | 2001-07-09 | 2010-06-15 | Repros Therapeutics Inc. | Methods and compositions with trans-clomiphene |
US20070197664A1 (en) * | 2001-11-29 | 2007-08-23 | Steiner Mitchell S | Prevention and treatment of androgen-deprivation induced osteoporosis |
US20040096510A1 (en) * | 2001-11-29 | 2004-05-20 | Steiner Mitchell S. | Prevention and treatment of androgen-deprivation induced osteoporosis |
US20060269611A1 (en) * | 2001-11-29 | 2006-11-30 | Steiner Mitchell S | Prevention and treatment of androgen-deprivation induced osteoporosis |
US7524866B2 (en) * | 2001-11-29 | 2009-04-28 | Gtx, Inc. | Prevention and treatment of androgen—deprivation induced osteoporosis |
US20050080143A1 (en) * | 2001-11-29 | 2005-04-14 | Steiner Mitchell S. | Treatment of androgen-deprivation induced osteoporosis |
US20040213841A1 (en) * | 2001-11-29 | 2004-10-28 | Steiner Mitchell S | Methods for treating hot flashes and gynecomastia |
US20040214898A1 (en) * | 2001-11-29 | 2004-10-28 | Steiner Mitchell S. | Methods for treating hot flashes |
BR0214801A (pt) | 2001-11-29 | 2005-01-11 | Gtx Inc | Prevenção e tratamento de osteoporose induzida pela privação de andrógeno |
US20080249183A1 (en) * | 2001-11-29 | 2008-10-09 | Steiner Mitchell S | Treatment of androgen-deprivation induced osteoporosis |
KR20030061474A (ko) * | 2002-01-14 | 2003-07-22 | 한미약품 주식회사 | 서트랄린 제조용 중간체로서 사용되는 시스-라세메이트화합물의 개선된 제조방법 |
FI114917B (fi) * | 2002-08-29 | 2005-01-31 | Hormos Nutraceutical Oy Ltd | Lignaanikomplekseja |
US7332525B2 (en) * | 2003-01-17 | 2008-02-19 | Castle Erik P | Method of treatment of prostate cancer and composition for treatment thereof |
US7461048B2 (en) * | 2003-07-21 | 2008-12-02 | Aureon Laboratories, Inc. | Systems and methods for treating, diagnosing and predicting the occurrence of a medical condition |
US7467119B2 (en) * | 2003-07-21 | 2008-12-16 | Aureon Laboratories, Inc. | Systems and methods for treating, diagnosing and predicting the occurrence of a medical condition |
WO2005050563A2 (en) * | 2003-11-17 | 2005-06-02 | Aureon Biosciences Corporation | Pathological tissue mapping |
US7070816B2 (en) * | 2003-12-05 | 2006-07-04 | New Chapter, Inc. | Methods for treating prostatic intraepithelial neoplasia with herbal compositions |
EP1728210A2 (en) * | 2004-02-27 | 2006-12-06 | Aureon Laboratories, Inc. | Methods and systems for predicting occurrence of an event |
MX2007000050A (es) * | 2004-07-14 | 2007-07-10 | Repros Therapeutics Inc | Trans-clomifeno para el tratamiento de hipertrofia de prostata benigna, cancer de prostata, hipogonadismo, trigliceridos elevados y colesterol elevado. |
EP2392322A3 (en) | 2005-03-22 | 2012-02-22 | Repros Therapeutics Inc. | Dosing regimes for trans-clomiphene |
US20060270641A1 (en) * | 2005-05-31 | 2006-11-30 | Steiner Mitchell S | Method for chemoprevention of prostate cancer |
WO2007135547A2 (en) * | 2006-05-22 | 2007-11-29 | Hormos Medical Ltd. | Selective estrogen receptor modulators or aromatase inhibitors for treating chronic nonbacterial prostatitis |
WO2009040824A2 (en) * | 2007-09-24 | 2009-04-02 | Ganga Raju Gokaraju | Anti-adipogenic compositions containing piper betel and dolichos bifloras |
CA2702710C (en) | 2007-10-16 | 2013-05-07 | Repros Therapeutics, Inc. | Trans-clomiphene for metabolic syndrome |
PT2616078T (pt) | 2010-09-16 | 2020-03-31 | Shimoda Biotech Pty Ltd | Composições de fulvestrant e métodos de uso |
UA113291C2 (xx) | 2011-08-04 | 2017-01-10 | Метаболіти транскломіфену і їх застосування | |
CA2889770A1 (en) | 2012-11-02 | 2014-05-08 | Repros Therapeutics Inc. | Trans-clomiphene for use in cancer therapy |
Family Cites Families (35)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4329364A (en) | 1974-09-11 | 1982-05-11 | Schering Corporation | Antiandrogenic agents and methods for the treatment of androgen dependent disease states |
US4474813A (en) | 1980-10-24 | 1984-10-02 | Schering Corporation | Pharmaceutical preparations comprising flutamide |
US4418068A (en) * | 1981-04-03 | 1983-11-29 | Eli Lilly And Company | Antiestrogenic and antiandrugenic benzothiophenes |
FI77839C (fi) | 1982-05-27 | 1989-05-10 | Farmos Oy | Foerfarande foer framstaellning av nya terapeutiskt effektiva trifenylalkan- och alkenderivat. |
GB2126576B (en) | 1982-06-25 | 1985-06-19 | Farmos Group Limited | Alkane and alkene derivatives |
US5491173A (en) * | 1982-06-25 | 1996-02-13 | Orion-Yhtyma Oy | Tri-phenyl alkene derivatives and their preparation and use |
US5595985A (en) | 1989-03-10 | 1997-01-21 | Endorecherche Inc. | Combination therapy for prophylaxis and/or treatment of benign prostatic hyperplasia |
US4990538A (en) | 1989-08-23 | 1991-02-05 | Harris Adrian L | Use of toremifene and its metabolites for the reversal of multidrug resistance of cancer cells against cytotoxic drugs |
GB9126209D0 (en) * | 1991-12-10 | 1992-02-12 | Orion Yhtymae Oy | Drug formulations for parenteral use |
GB9207437D0 (en) * | 1992-04-03 | 1992-05-20 | Orion Yhtymae Oy | Topical administration of toremifene and its metabolites |
US5847007A (en) | 1993-05-13 | 1998-12-08 | Neorx Corporation | Prevention and treatment of pathologies associated with abnormally proliferative smooth muscle cells |
JP3566741B2 (ja) * | 1992-10-27 | 2004-09-15 | 日本化薬株式会社 | 自己免疫疾患治療薬 |
DE69329802T2 (de) * | 1992-12-01 | 2001-07-19 | Biotie Therapies Corp | Syndecan-stimulierung der zellulären differenzierung |
US5595722A (en) | 1993-01-28 | 1997-01-21 | Neorx Corporation | Method for identifying an agent which increases TGF-beta levels |
RU2153332C2 (ru) | 1993-08-09 | 2000-07-27 | Орион Корпорейшн | Способ сенсибилизации раковых клеток к лизису, опосредованному клетками-киллерами |
IL112746A (en) * | 1994-03-02 | 1999-12-31 | Lilly Co Eli | Orally administrable pharmaceutical formulation comprising raloxifene hydrochoride |
US5811120A (en) * | 1994-03-02 | 1998-09-22 | Eli Lilly And Company | Solid orally administerable raloxifene hydrochloride pharmaceutical formulation |
US5972383A (en) * | 1994-03-02 | 1999-10-26 | Eli Lilly And Company | Solid orally administerable raloxifene hydrochloride pharmaceutical formulation |
US5650425A (en) | 1994-04-04 | 1997-07-22 | Pharmos Corporation | Permanently ionic derivatives of steroid hormones and their antagonists |
US5441986A (en) * | 1994-07-19 | 1995-08-15 | Pfizer Inc. | Estrogen agonists as remedies for prostate and cardiovascular diseases |
US5821254A (en) * | 1995-02-17 | 1998-10-13 | The United States Of America As Represented By The Department Of Health And Human Services | Uses of 9-cis-retinoic acids and derivatives thereof alone or in combination with antineoplastic agents in the prevention or treatment of cancer |
US5629007A (en) | 1995-03-21 | 1997-05-13 | Eli Lilly And Company | Method of preventing prostatic cancer development |
US5635197A (en) | 1995-03-21 | 1997-06-03 | Eli Lilly And Company | Treatment and prevention of prostatic cancer metastasis |
DE19526146A1 (de) * | 1995-07-07 | 1997-01-09 | Schering Ag | Triphenylethylene, Verfahren zu deren Herstellung, diese Triphenylethylene enthaltene pharmazeutische Präparate sowie deren Verwendung zur Herstellung von Arzneimitteln |
US5728707A (en) * | 1995-07-21 | 1998-03-17 | Constantia Gruppe | Treatment and prevention of primary and metastatic neoplasms with salts of aminoimidazole carboxamide |
US5726202A (en) * | 1996-01-11 | 1998-03-10 | Novo Nordisk A/S | Benign prostatic hypertrophy |
US5883118A (en) * | 1996-01-11 | 1999-03-16 | Nova Nordisk A/S | Prostatic carcinoma |
US5859045A (en) * | 1996-05-08 | 1999-01-12 | Novo Nordisk A/S Novo Alle | Crystalline -! 3R 4R-trans-7 methoxy 2,2-dimethyl1-3-phenyl 1-4 4-12 pyrrolidin-1 -Y1!ethoxyl 1!chromane hydrogen fumarate |
ATE196844T1 (de) * | 1996-05-22 | 2000-10-15 | Protarga Inc | Zusammensetzungen die konjugate von cis- docosahexaenoic-säure und taxotere enthalten |
ZA982819B (en) * | 1997-04-09 | 1999-10-04 | Lilly Co Eli | Treatment or prophylaxis of prostatic cancer and benign prostatic hyperplasia with selective estrogn receptor modulators. |
ZA984650B (en) | 1997-06-19 | 1998-12-08 | Orion Corp | Intratumoral administration of triphenylethylenes for the treatment of cancer |
EP1019057B1 (en) * | 1997-08-15 | 2008-10-15 | Duke University | A method of preventing or treating estrogen-dependent diseases and disorders |
GB9805868D0 (en) * | 1998-03-20 | 1998-05-13 | Zeneca Ltd | Anti-tumour agents |
JP4482229B2 (ja) * | 1998-05-07 | 2010-06-16 | ユニバーシティ オブ テネシー リサーチ ファウンデーション | 前立腺癌の化学防御方法 |
AU6291699A (en) * | 1998-10-06 | 2000-04-26 | Kgk Synergize | Compositions and methods of inhibiting neoplastic diseases with compounds related to limocitrin and 5-desmethyl sinensetin |
-
2000
- 2000-03-20 US US09/531,472 patent/US6413533B1/en not_active Expired - Fee Related
- 2000-11-08 JP JP2001536117A patent/JP2003513903A/ja active Pending
- 2000-11-08 EP EP00978418A patent/EP1229903A4/en not_active Withdrawn
- 2000-11-08 AU AU15884/01A patent/AU782444B2/en not_active Ceased
- 2000-11-08 PL PL00354726A patent/PL354726A1/xx unknown
- 2000-11-08 WO PCT/US2000/030658 patent/WO2001034117A1/en active Search and Examination
- 2000-11-08 MX MXPA02004676A patent/MXPA02004676A/es not_active Application Discontinuation
- 2000-11-08 CZ CZ20021763A patent/CZ20021763A3/cs unknown
- 2000-11-08 CA CA002390295A patent/CA2390295C/en not_active Expired - Fee Related
- 2000-11-08 HU HU0203304A patent/HUP0203304A3/hu unknown
- 2000-11-08 CN CNB008182280A patent/CN1331463C/zh not_active Expired - Fee Related
- 2000-11-08 KR KR1020027005967A patent/KR100793721B1/ko not_active IP Right Cessation
- 2000-11-08 SK SK816-2002A patent/SK8162002A3/sk not_active Application Discontinuation
- 2000-11-08 IL IL14954500A patent/IL149545A0/xx unknown
- 2000-11-08 YU YU43002A patent/YU43002A/sh unknown
- 2000-11-08 KR KR1020067024871A patent/KR20060130788A/ko not_active Application Discontinuation
-
2002
- 2002-05-08 IS IS6375A patent/IS6375A/is unknown
- 2002-05-08 NO NO20022221A patent/NO20022221L/no not_active Application Discontinuation
- 2002-05-15 HR HR20020422A patent/HRP20020422A2/xx not_active Application Discontinuation
- 2002-05-22 BG BG106738A patent/BG65794B1/bg unknown
-
2003
- 2003-11-28 HK HK03108685A patent/HK1057000A1/xx not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
HUP0203304A3 (en) | 2006-02-28 |
BG106738A (en) | 2003-02-28 |
WO2001034117A9 (en) | 2002-05-10 |
SK8162002A3 (en) | 2003-03-04 |
KR100793721B1 (ko) | 2008-01-10 |
BG65794B1 (bg) | 2009-12-31 |
WO2001034117A1 (en) | 2001-05-17 |
NO20022221D0 (no) | 2002-05-08 |
CN1420765A (zh) | 2003-05-28 |
KR20020070276A (ko) | 2002-09-05 |
US6413533B1 (en) | 2002-07-02 |
CZ20021763A3 (cs) | 2003-02-12 |
AU1588401A (en) | 2001-06-06 |
HK1057000A1 (en) | 2004-03-12 |
CA2390295A1 (en) | 2001-05-17 |
KR20060130788A (ko) | 2006-12-19 |
CA2390295C (en) | 2009-09-29 |
MXPA02004676A (es) | 2004-09-10 |
CN1331463C (zh) | 2007-08-15 |
JP2003513903A (ja) | 2003-04-15 |
YU43002A (sh) | 2005-09-19 |
HUP0203304A2 (hu) | 2003-02-28 |
EP1229903A4 (en) | 2006-06-07 |
IS6375A (is) | 2002-05-08 |
AU782444B2 (en) | 2005-07-28 |
IL149545A0 (en) | 2002-11-10 |
HRP20020422A2 (en) | 2004-04-30 |
EP1229903A1 (en) | 2002-08-14 |
PL354726A1 (en) | 2004-02-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NO20022221L (no) | En fremgangsmåte til en kjemisk forhindring av prostatakreft | |
NO20045429L (no) | Kombinasjon av organiske forbindelser | |
NO20050525L (no) | Benzimidazol-1-yl-tiofenforbindelser for behandling av cancer | |
AU2002327180A1 (en) | Detection and therapy of vulnerable plaque with photodynamic compounds | |
NO20055863L (no) | W-karboksyarylsubstituerte difenylureaforbindelser som raf-kinaseinhibitorer | |
NO20072352L (no) | Forbindelser og sammensetninger som inhibitorer av cannabinoidreceptor 1-aktivitet | |
NO20081042L (no) | PPAR aktive forbindelser | |
NO20080150L (no) | Inhibitorer av AKT-aktivitet | |
WO2001081310A8 (en) | 1-aroyl-piperidinyl benzamidines | |
MX366328B (es) | (+)-2-[1-(3-etoxi-4-metoxifenil)-2-metilsulfoniletil]-4-acetilami noisoindolin-1,3-diona: metodos de uso y composiciones de la misma. | |
CY1107174T1 (el) | Συνδυασμοι εζετιμιβε με ασπιρινη για θεραπεια αγγειακων καταστασεων | |
DK1624878T3 (da) | Anvendelse af præparater som omfatter en östrogen komponent til behandling og forebyggelse af muskel-skelet-smerte | |
BR0013767A (pt) | Aminoalcoxicarbazóis para tratamento de doenças do snc | |
CA2323809A1 (en) | A method for chemoprevention of prostate cancer | |
DK1506185T3 (da) | Forbindelser og deres anvendelse som 5-HT-inhibitorer | |
MA26975A1 (fr) | 2-azetinones substituees par des sucres utilisees comme agents hypocholesterolemiants | |
DK1066056T4 (da) | Jerndextranforbindelse til anvendelse som komponent i et terapeutisk middel til forebyggelse af eller behandling af jernmangel, fremgangsmåde til fremstilling af jerndextranforbindelsen og anvendelse af denne forbindelse til fremstilling af et... | |
NO20051168L (no) | Anvendelse av fermentert hvetekimekstrakt som anti-inflammasjonsmiddel | |
CL2015001086A1 (es) | Combinación farmacéutica para el tratamiento y/o quimiosensibilizacion de tumores refractarios a drogas anticancerigenas | |
WO2004043456A8 (en) | Cholesterol absorption inhibitors for the treatment of demyelination | |
ATE443044T1 (de) | Tace inhibitoren | |
WO2003024405A3 (en) | Methods and compositions for inhibiting the proliferation of prostate cancer cells | |
BR9812780A (pt) | 2-aril-3-aroilbenzo[b]tiofenos úteis para o tratamento de sìndrome da perda de estrogênio | |
DE60316128D1 (de) | N-sulfonylurea-apoptosis-förderer | |
BR0308601A (pt) | inibidores de carboxipeptidase b de plasma |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FC2A | Withdrawal, rejection or dismissal of laid open patent application |